文献速递中医内科中药与中成药合理使用

改良丁桂散脐疗治疗慢性非细菌性前列腺炎的随机双盲安慰剂对照试验

Effectiveness and Safety of Umbilicus Treatment with Modified Dinggui Powder () in Patients with Chronic Nonbacterial Prostatitis: A Randomized, Double-blind, Placebo-controlled Clinical Trial.
PubMed 文献 · Chin J Integr Med · 2020-04-01

该随机双盲安慰剂对照试验纳入72例慢性非细菌性前列腺炎患者,比较改良丁桂散脐疗与安慰剂贴敷神阙穴(均联合中药内服)的疗效与安全性。结果显示脐疗组在疼痛评分、症状严重程度、总分及前列腺液白细胞数方面改善更优,临床有效率更高,且无严重不良事件。

要点

  • 改良丁桂散脐疗可改善CNP患者疼痛与症状严重程度。
  • 脐疗组临床有效率73.53%,高于安慰剂组的48.39%。
  • 试验期间未发现严重不良事件,盲法实施成功。

核心结论

  • 4周改良丁桂散脐疗可有效缓解CNP患者疼痛和症状严重程度,并增加前列腺液白细胞数量。

研究设计与样本

  • 随机、双盲、安慰剂对照临床试验,共纳入72例CNP患者,按1:1比例随机分为治疗组36例和安慰剂对照组36例。
  • 两组均贴敷神阙穴(CV 8),每周2次,持续4周,同时所有患者均接受中药内服治疗每日2次、持续4周。

主要发现

  • MDGP组在第2周(P<0.001)和第4周(P=0.004)的NIH-CPSI疼痛或不适评分改善均优于安慰剂对照组。
  • MDGP组NIH-CPSI症状严重程度评分、总分及前列腺液白细胞数量均显著改善(P<0.05)。
  • 两组在排尿症状、生活质量、卵磷脂小体及其他评分方面无统计学差异(P>0.05)。
  • MDGP组临床有效率为73.53%(25/34),显著高于安慰剂对照组的48.39%(25/31,P<0.05)。
  • 患者盲法实施成功,试验期间未发现严重不良事件。

关键数值与推荐

  • 主要结局为美国国立卫生研究院慢性前列腺炎症状评分指数(NIH-CPSI)问卷,于第2周和第4周评估。
  • 次要结局包括前列腺液检查(白细胞和卵磷脂小体)、临床疗效评价及不良事件。

临床怎么用

  • 对于CNP患者,可考虑在中药内服基础上联合改良丁桂散脐疗贴敷神阙穴,每周2次、持续4周,以改善疼痛及症状严重程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness and safety of Chinese herbal external umbilicus treatment with Modified Dinggui Powder (, MDGP) in patients with chronic nonbacterial prostatitis (CNP). METHODS: A randomized, double-blind, placebo-controlled clinical trial was conducted among 72 patients with CNP. Participants were randomly allocated to a treatment group and a placebo group using computer software in a 1:1 ratio, and received either MDGP external umbilicus treatment (MDGP group, 36 cases) or placebo control groupl (36 cases) at acupoints Shenque (CV 8), twice a week for 4 weeks. In addtion, patients all received herbal medicine treatment twice a day for 4 weeks. The primary outcomes was the US National Institutes of Health Chronic Prostatitis Symptom Scores Index (NIH-CPSI) with a questionnaire at weeks 2 and 4. The secondary outcomes including prostatic fluid examination (white blood cells and lecithin bodies), the clinical efficacy evaluation, and the adverse events were also assessed during the entire trial. RESULTS: The NIH-CPSI scores regarding pain or discomfort scores showed greater improvement in the MDGP group than placebo control group at weeks 2 (P0.001) and week 4 (P0.004), respectively. NIH-CPSI scores of symptom severity, total scores, the amount of leukocytes number in the prostatic fifluid in the MDGP group were significantly improved (P<0.05). There was no statistical difference in the urinary symptoms, quality of life, lecithin and other scores between two groups (P>0.05). The clinical effective rate was 73.53% (25/34) in the MDGP group, which was significally higher than the placebo control group with 48.39% (25/31, P<0.05). Patients were blinded successfully, and no serious adverse effects were found during the trial. CONCLUSION: A 4-week course of umbilicus treatment with modified Dinggui Powder seems to relieve pain and symptom severity effectively and increase the amount of leukocytes number in patients with CNP (Trial registration No. ChiCTR1800014687).

来源:Chin J Integr Med,查看原文。版权归原作者所有。

引用

  1. Huang H, Zhou MJ, Wang KX, et al. Effectiveness and Safety of Umbilicus Treatment with Modified Dinggui Powder () in Patients with Chronic Nonbacterial Prostatitis: A Randomized, Double-blind, Placebo-controlled Clinical Trial. Chin J Integr Med. 2020. PMID: 32240476. doi:10.1007/s11655-020-3258-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。